Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Systematic review and meta-analysis for 2023 clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis.
Watanabe R, Oshima M, Nishioka N, Sada KE, Nagasaka K, Akiyama M, Ando T, Higuchi T, Inoue Y, Kida T, Mutoh T, Nakabayashi A, Onishi A, Sakai R, Waki D, Yamada Y, Yajima N, Tamura N, Kaname S, Harigai M. Watanabe R, et al. Mod Rheumatol. 2023 Aug 25;33(5):982-989. doi: 10.1093/mr/roac114. Mod Rheumatol. 2023. PMID: 36112482
Successful multi-target therapy using corticosteroid, tacrolimus, cyclophosphamide, and rituximab for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis.
Watanabe R, Ishii T, Araki K, Ishizuka M, Kamogawa Y, Fujita Y, Shirota Y, Fujii H, Harigae H. Watanabe R, et al. Mod Rheumatol. 2016;26(3):465-6. doi: 10.3109/14397595.2015.1012797. Epub 2015 Jun 29. Mod Rheumatol. 2016. PMID: 25698368 No abstract available.
Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus.
Ishii T, Tanaka Y, Kawakami A, Saito K, Ichinose K, Fujii H, Shirota Y, Shirai T, Fujita Y, Watanabe R, Chiu SW, Yamaguchi T, Harigae H. Ishii T, et al. Among authors: watanabe r. Mod Rheumatol. 2018 Nov;28(6):986-992. doi: 10.1080/14397595.2018.1432331. Epub 2018 Feb 15. Mod Rheumatol. 2018. PMID: 29363990 Clinical Trial.
Favorable clinical response and drug retention of anti-IL-6 receptor inhibitor in rheumatoid arthritis with high CRP levels: the ANSWER cohort study.
Nakayama Y, Hashimoto M, Watanabe R, Murakami K, Murata K, Tanaka M, Ito H, Yamamoto W, Ebina K, Hata K, Hiramatsu Y, Katayama M, Son Y, Amuro H, Akashi K, Onishi A, Hara R, Yamamoto K, Ohmura K, Matsuda S, Morinobu A. Nakayama Y, et al. Among authors: watanabe r. Scand J Rheumatol. 2022 Nov;51(6):431-440. doi: 10.1080/03009742.2021.1947005. Epub 2021 Sep 13. Scand J Rheumatol. 2022. PMID: 34511031
2,177 results